Security key
29479A108
CUSIP: 29479A108
Security key
29479A108
Report period
Q2 2025
Institutions
141
Top holders
10
Broader feeds
Reporting periods
Recent filing periods:
Ownership snapshot
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Rank 1 holder
Rank 2 holder
Rank 3 holder
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Frazier Life Sciences Public Fund, L.P. |
13D/G
|
5.3%
|
$21,355,029
15,038,753 shares
|
-$10,702,679 | 30 Jun 2025 |
| NOVARTIS PHARMA AG |
13D/G
|
4.4%
|
$17,107,692
12,307,692 shares
|
$0 | 31 Dec 2024 |
| Frazier Life Sciences Management, L.P. |
13F
Company
|
7.3%
|
$30,928,916
22,575,851 shares
|
— | 31 Mar 2025 |
| T. Rowe Price Investment Management, Inc. |
13F
Company
|
5.6%
|
$23,691,000
17,292,164 shares
|
— | 31 Mar 2025 |
| Venrock Adviser, LLC |
13F
Company
|
5.2%
|
$22,216,216
16,216,216 shares
|
— | 31 Mar 2025 |
| BlackRock, Inc. |
13F
Company
|
5%
|
$21,370,366
15,598,808 shares
|
— | 31 Mar 2025 |
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Investor-level positions for this CUSIP, loaded as an interactive table.
| Investor | Option | Weight % | Change % | Reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* Reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that failed the local validity check.
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).